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Life, in the form as we know it – is inseparable from motility, the capability of a 
living system to perform active movement. Motility is driven by special enzymes 
called molecular motors, which have the ability to convert chemical energy into 
mechanical energy. Blebbistatin is a cell permeable, specific inhibitor of class II 
myosins, a group of actin based ATP-driven motor proteins responsible for various 
biological processes, including muscle contraction, cell migration, differentiation, 
blebbing and cytokinesis. Although blebbistatin is the most deeply characterized  and 
most widely used myosin II specific inhibitor, it has several limitations: 1. its high 
fluorescence can interfere with fluorescence based  measurements, 2. photoinstability 
and phototoxicity upon blue light excitation, 3. cytotoxicity even without irradiation. 
Besides the myosin II specificity of blebbistatin, emerging evidence indicate that 
blebbistatin may interact with partners other than myosin II. In order to determine all 
binding partners of blebbistatin, we have synthesized the azido derivative of 
blebbistatin, azidoblebbistatin, and applied photoaffinity labeling (PAL) for target 
deconvolution. In PAL, the ligand - which is usually a small bioactive molecule - is 
supplemented with a photoreactive group (label), then introduced into the studied 
system and subjected to UV irradiation. Photolysis of the label results in a highly 
reactive intermediate capable to form covalent bond with the nearest reactive group in 
the ligand's binding site. In PAL experiments, arylazide derivatives are used the most 
often because of  their chemical stability in the absence of UV irradiation, their 
biological inertness and the small size of the azido group. After we proved that 
azidoblebbistatin has identical myosin II  inhibitory properties to  blebbistatin's, and 
azidoblebbistatin can be photocrosslinked to myosin II, we confirmed that the most 
specific target of blebbistatin in Dd cells is myosin II (EC50≈5 µM), although at higher 
inhibitor concentrations we identified several weak-binding partners as well (EC50>30 
µM). During the characterization of azidoblebbistatin, we found that unlike 
blebbistatin, it is not phototoxic. This observation inspired us to synthesize para-
nitroblebbistatin, where the azido group was replaced by a non-photoreactive nitro 
group, which has similar electron withdrawing characteristics. We proved by in vitro 
and in vivo experiments that para-nitroblebbistatin lacks all of the adverse effect of 
blebbistatin (photoinstability, fluorescence, cyto- and phototoxicity)  while its myosin 
II inhibitory properties are unaffected, providing an unrestricted alternative of 
blebbistatin both in vitro and in vivo. Applying azidated compounds, we proved that 
PAL - besides UV irradiation - can also be triggered by two-photon irradiation (2PM) 
and realized that this reaction can serve as a basis for a new optopharmacological drug 
targeting technique, which we named molecular tattooing. Molecular tattooing 
delivers and covalently attaches a photoreactive bioactive compound to its specific 
target by two-photon irradiation. The biological effect of the compound can be 
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confined to even subfemtoliter volumes with no systemic effects outside the targeted 
area. Using single cell and live animal experiments we demonstrated how molecular 
tattooing can be applied to localize the effect of drugs even into subcellular regions.   
 
Aims 
• Chemical synthesis of azidated bioactive compounds 
• in vitro and in vivo characterization of azidoblebbistatin, the first 
photoinduciable myosin II inhibitor 
• photocrosslink of the myosin-azidoblebbistatin complex  
• Target deconvolution of blebbistatin 
• Chemical synthesis of C15 nitro and chloro substituted derivatives of 
blebbistatin 
• measure the photochemical behavior, the in vitro and in vivo myosin 
inhibition of para-nitroblebbistatin 
• characterization of two-photon activation of azidated compounds 
• Spatiotemporal targeting of myosin II in live zebrafish embryo by 
azidoblebbistatin 
• Exploring the role of myosin II in the blebbing mechanism of M2 melanoma 
cells by subcellular targeting with azidoblebbistatin 
 
Results 
1. Chemical synthesis of the aryl azido derivatives of 9 bioactive compounds. 
We have developed the synthesis of 9 azido-modified bioactive compounds including 
antipsychotics, COX inhibitors, sodium channel blockers, myosin inhibitors and an 
angiotensin 2 receptor antagonist. 
   
2. The aryl azido derivative of blebbistatin, azidoblebbistatin has identical 
myosin II  inhibitory properties to that of blebbistatin both  in vitro and in vivo.  
We have compared the myosin II inhibition of azidoblebbistatin and blebbistatin on 
the basal ATPase activities of DdMD (Dictyostelium discoideum myosin II motor 
domain), on the growth of Dd (Dictyostelium discoideum) cells in suspension culture 
and on the migration of zebrafish's pLLp (posterior lateral line primordium). In every 
cases we observed identical myosin inhibition by the two inhibitors.  
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3. Azidoblebbistatin can be photocrosslinked to myosin resulting in a covalently 
bound and inhibited enzyme-inhibtor complex. 
Azidoblebbistatin was photocrosslinked to myosin in myosin enriched cell lysate 
while the existence of the covalently bound enzyme-inhibtor complex was detected by 
MS. Additionally, it was demonstrated that myosin can be covalently saturated by low 
concentrations of azidoblebbistatin using the technique of sequential crosslinking 
(subsequent azidobelbbistatin addition and UV irradiation cycles).  
4. The most specific target of blebbistatin in Dd cells is myosin II (EC50≈5 µM) 
although at higher inhibitor concentrations (>30 µM) blebbistatin has several weak 
binding partners.   
We prepared Dd whole cell lysate as well as myosin-enriched fractions of the lysate of 
a Dd cell line expressing recombinant DdMd, and subjected the samples to increasing 
concentrations of azidoblebbistatin and UV irradiation. Samples were analyzed by 
SDS-PAGE by utilizing the fluorescence signal of azidoblebbistatin. We observed six 
distinct fluorescent bands in the myosin-enriched fractions, which were analyzed by 
densitometry and mass spectrometry. The analysis showed that azidoblebbistatin binds 
most specifically to myosin 2 heavy chain (EC50 = 5.1 ± 1.4 µM) and its degradation 
product (EC50 = 9.3 ± 3.7 µM) as well as DdMd (EC50 = 5.2 ± 0.8 µM). Further, 
previously unknown low-affinity (EC50 ≥ 30 µM) interacting partners of 
azidoblebbistatin were also identified.  
5. The para-position of the phenyl ring of blebbistatin (C15) can be modified by 
electron withdrawing substituents without affecting the myosin inhibitory properties of 
the derivatives. 
We have synthesized C15 substituted azido, nitro and chloro derivatives of 
blebbistatin and measured their in vitro and in vivo myosin inhibition. Based on our 
results we concluded that the C15 position of blebbistatin tolerates modifications.     
6. Para-nitro substituted blebbistatin, para-nitroblebbistatin is photostable, 
non-fluorescent, non-cytotoxic and  non-phototoxic. 
The C15 nitro substitution of blebbistatin greatly reduces its fluorescence, improves 
its photostability, eliminates its cyto- and phototxicity without effecting the myosin II 
inhibitory properties of the molecule. Thus, para-nitroblebbistatin serves as an 
unrestricted and complete replacement of blebbistatin both in vitro and in vivo. 
7. Myosin II is required for scission, the final step of cell division. 
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The non-phototoxicity of para-nitroblebbistatin enables fluorescent microscopic 
imaging of living organisms providing novel insights into the role of myosin IIs in 
vivo. When we time-lapse imaged HeLa Kyoto cells treated with para-
nitroblebbistatin at low concentrations (<30 µM), we observed a hitherto undescribed 
phenotype in HeLa cells: after anaphase, the cytokinesis proceeded, the midbody 
formed but scission did not occur. After a while the cell collapsed and became 
binuclear (mechanism 1). We also found that treatment with high concentrations (>30 
µM) of para-nitroblebbistatin inhibited the ingression of the cleavage furrow 
(mechanism 2) in which case cytokinesis did not occur. However, according to our 
results, para-nitroblebbistatin is not specific at high concentrations which indicates 
that only mechanism 1 can be attributed to the inhibition of myosin II.  Consequently, 
scission - the final stage of cell division - requires the activity of myosin IIs. The 
significance of the observation is highlighted by the fact that no myosin II 
involvement has been reported in scission yet. 
8. 2P induced photocrosslinking reaction of aryl azido derivatives of bioactive 
compounds can be used for their effect  confinement with subfemtoliter resolution 
without any observable systemic effects outside the targeted area. 
We demonstrated that using photo-crosslinking cycles, azidoblebbistatin can 
covalently saturate its target enzyme, myosin II, even at non-saturating concentrations 
of azidoblebbistatin. Furthermore, we revealed that photoactivation can be initiated by 
two-photon excitation, enabling the localization of the effect into subfemtoliter 
volumes. Based on these two observation we realized that 2P induced sequential 
crosslinking can be used for effect confinement of azidated bioactive compounds: if a 
whole organism is treated with low concentrations of an azidated bioactive compound 
(i.e. [enzyme inhibitor] << EC50), its specific effect cannot be observed. However, if 
a defined area (i.e. a cell or subcellular region) is illuminated continuously  by two-
photon irradiation, it results in the local saturation of the target enzyme  as a 
consequence of two phenomena: covalent attachment of the azidated ligand to its 
target and the continuous diffusion of the unreacted azidated ligand molecules from 
the environment into the site of irradiation (Figure 1). 
9. Bleb expansion in M2 melanoma cells is driven by globally uniform pressure  
while bleb retraction requires local myosin 2 activity. 
Myosin 2 activity was inhibited subcellularly in blebbing M2 melanoma cells by 
subcellular molecular tattooing, revealing that bleb expansion is driven by globally 
uniform hydrostatic pressure while local myosin 2 activity is solely needed for the 





• the chemical synthesis of azidated drugs can be efficiently performed using 
iodinated precursors and halogen azide exchange reactions. The synthesis is 
greatly aided by the fact that in case of many pharmaceutical agents the synthetic 
route of their iodo derivative  has been explored due to the need of SAR 
(Structure Activity Relationship), radiolabeling for receptor binding assays, 
ADME (Absorption, Distribution, Metabolism, and Excretion) or SPECT (Single 
Photon Emission Computed Tomography) imaging. 
• photocrosslinking of azidated compounds can be used as an efficient  
technological solution for interactome profiling, adequate for the experimental 
determination of the apparent binding constants  of the strong as well as weak-
binding protein-ligand complexes. 
• C15 nitro substitution of 
blebbistatin eliminates the 
unwanted effects of the 
inhibitor without altering its 
myosin II inhibition. The 
unaffected inhibitory 
properties of para-
nitroblebbistatin can be 
explained by the analysis of 
the crystal structure of the 
myosin.ADP.Vi.blebbistatin 
complex (PDB: 1YV3): the 
C15 nitro substitution of 
blebbistatin does not affect 
significantly the  interaction 
of the inhibitor with myosin 
since  the substituted group 
causes no steric hindrance 
with any of the side chains in the binding site (Figure 1). 
• Two-photon induced photoaffinity labeling reaction can be used for 
spatiotemporal in vivo effect confinement of azidated bioactive compounds. This 
technology, what we named molecular tattooing, enables the investigation of 
local and global molecular mechanisms, autonomous or non-autonomous cellular 









Figure 2. The concept of molecular tattooing. Azidated compounds - i.e. azidoblebbistatin 
(Ableb) - are designed to preserve their biological activity. They bind to the target enzyme - i.e. 
Myosin II (M) - and upon irradiation the bound portion of the azidated compound covalently 
attaches to its target while the unbound molecules react with water and become photo-inactive. 
This process depletes the azido compound in the irradiated target area. Since the influx of the 
non-reacted, active azidated compounds into the depleted area is rapid, multiple scanning of the 
target area leads to the covalent saturation of the target enzyme. Thus, in molecular tattooing 
low concentration of the azidated compound can be applied even much below EC50 within the 
whole organism which guarantees the lack of drug effect in the off-target areas. Microscopic 
imaging was performed by a 2PM after tattooing of a HeLa cell with azidoblebbistatin (MT 
shape, green). The actin network and the nuclei were stained by actin glow (red) and Hoescht 





• Organic chemistry: electrophilic substitutions (halogenations), copper (I) 
catalyzed halogen-azide exchange reactions, esterification, tosylation, 
asymmetric synthesis, microwave promoted synthesis    
• Flash chromatography, HPLC (High Pressure Liquid Chromatography), LC-MS 
(Liquid Chromatography-Mass Spectrometry) 
• NMR (Nuclear Magnetic Resonance Spectroscopy) - performed by Andrea 
Bodor 
• Protein expression and purification - performed by Ozoróczyné Ilona Szász 
• Absorption spectroscopy (Schimadzu UV-2101 spectrophotometer)  
• Fluorescent spectroscopy (Edinburgh Instruments F900 Fluorescence 
Spectrometer)  
• Steady-state basal and actin activated ATPase activities measurements - 
performed by Boglárka Várkuti and László Végner 
• Gel electrophoresis 
• Identification of tryptic protein fragments by MALDI-TOF (Matrix-Assisted 
Laser Desorption/Ionization-Time Of Flight) mass spectrometry - performed by 
Éva Gulyás 
• Cellular assays (Dd, HeLa, M2) 
• Live animal experiments (zebrafish) 
• Confocal microscopy (LSM 710, Zeiss) 
• Two-photon microscopy (Femto 2D, Femtonics) 
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